You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 6, 2024

CLINICAL TRIALS PROFILE FOR PROHANCE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for PROHANCE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00522951 ↗ SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study Completed Bayer Phase 3 2007-08-01 This study is conducted to compare the contrast effect and safety of SH L562BB with ProHance, which has already been approved as a pharmaceutical product of similar indication.
NCT00709852 ↗ Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging Completed Bayer Phase 3 2008-06-01 This study involves the use of Magnetic Resonance Imaging (MRI) contrast agents called gadobutrol (Gadavist) Injection and ProHance Injection. The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of gadobutrol when used for taking MR images of the brain and spine. The results of the MRI with gadobutrol Injection will be compared to the results of MR images taken without contrast and with the results of the MR images taken with ProHance.
NCT01019486 ↗ Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D) Completed University of Colorado, Denver Phase 4 2009-11-01 Cardiovascular disease (CVD) remains the major cause of mortality and morbidity in both type 1 (T1D) and type 2 (T2D) diabetes patients; modifications of traditional CVD risk factors have had a limited impact. This project called Regadenoson Blood flow in Type 1 Diabetes (RABIT1D) and is proposed as a sub-study of the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study, which has established a unique cohort of 656 T1D patients (age 20-55, minimal diabetes duration of 10 yrs) and 764 non-diabetic controls. This cohort is being followed for progression of coronary artery calcification (CAC) measured using the electron beam tomography (EBT) for development of clinical CVD. Participants have been well characterized during the baseline examination (4/00-3/02) and two follow-up re-examinations 3 and 6 years later. The study has provided important insights into the risk factors and possible prevention of premature CVD in T1D. We are proposing assess a subset of this population to determine vasodilatory reserve as it relates to early coronary atherosclerosis in T1D. Hypothesis: that myocardial blood imaging (MBF) reserve can be measured in Type 1 diabetes mellitus (DM) using regadenoson stress cardiac magnetic resonance and that significantly reduced MBF is a marker of extensive atherosclerotic disease correlated to coronary arterial calcification, plaque formation and impaired vasodilatory reserve.
NCT01613417 ↗ Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain Completed Bracco Diagnostics, Inc Phase 4 2012-08-01 This study aims at a direct comparison between ProHance (0.1 mmol/kg) and a validated comparator Gadovist/Gadavist (0.1 mmol/kg) in a crossover intra-individual design in subjects with brain tumors to confirm the identical overall technical and diagnostic performance of the two MR contrast agents.
NCT02359097 ↗ Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma Completed National Cancer Institute (NCI) N/A 2015-01-06 This clinical trial studies steady state blood volume maps using ferumoxytol non-stoichiometric magnetite magnetic resonance (MRI) in imaging patients with glioblastoma. MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. Contrast agents, such as ferumoxytol non-stoichiometric magnetite, may enhance these pictures and increase visibility of tumor cells and the blood vessels in and around the tumors.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for PROHANCE

Condition Name

Condition Name for PROHANCE
Intervention Trials
Central Nervous System Diseases 1
Type 1 Diabetes Mellitus 1
Cognitive Function 1
Contrast Media 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for PROHANCE
Intervention Trials
Breast Neoplasms 2
Brain Neoplasms 1
Diabetes Mellitus 1
Sclerosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for PROHANCE

Trials by Country

Trials by Country for PROHANCE
Location Trials
United States 28
Japan 16
Germany 11
Colombia 4
Austria 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for PROHANCE
Location Trials
Alabama 3
Ohio 2
North Carolina 2
Massachusetts 2
Illinois 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for PROHANCE

Clinical Trial Phase

Clinical Trial Phase for PROHANCE
Clinical Trial Phase Trials
Phase 4 3
Phase 3 2
Phase 1 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for PROHANCE
Clinical Trial Phase Trials
Completed 5
Recruiting 2
Unknown status 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PROHANCE

Sponsor Name

Sponsor Name for PROHANCE
Sponsor Trials
Bayer 2
University of Alabama at Birmingham 2
IQVIA (Sponsor) 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for PROHANCE
Sponsor Trials
Other 10
Industry 4
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.